Once again, independent pharmacy owners are doing better than you might expect. In 2013, overall profits increased (again), while the average pharmacist owning a single pharmacy earned about $247,000. The number of independent pharmacies continues to hold steady.

Bottom line: Smaller independent pharmacies remain an important and healthy industry segment. Keep that in mind when pharmacies ask for any new special legislative protections.

As always, I welcome your constructive comments. Just remember our Drug Channels philosophy, courtesy of the late senator Patrick Moynihan: "Everyone is entitled to his own opinion, but not his own facts."THE NCPA DIGEST DATA

This year, NCPA decided not to release the detailed financials. Perhaps NCPA didn't want to advertise the good profit news. (Plausible deniability?) However, a little algebra plus some educated guesswork gives us everything we need.

Gross profit equals a pharmacy’s revenues minus the costs of products (net of discounts and returns) bought from a manufacturer or a wholesaler. Gross margin expresses gross profit as a percentage of revenues. A drugstore’s total revenues come from prescription drugs, over-the-counter products, vitamins, cosmetics, groceries, and other merchandise. A typical independent pharmacy generates more than 90% of its revenues from prescriptions.

Gross profit measures the portion of revenues available for a pharmacy's operating expenses and operating income. Operating expenses include: (1) Non-Owner Payroll Expenses—the wages, taxes, and benefits paid to the pharmacy’s staff, (2) Owner Compensation—the wages, taxes, and benefits paid to the working pharmacy owner, and (3) General Business Expenses—everything else needed to run the pharmacy, such as rent, utilities, licenses fees, insurance, advertising, and other business costs. Operating income equals gross profits minus operating expenses.

To be profitable, a pharmacy’s gross profits must exceed its operating expenses. For example, increasing Owner Compensation will decrease operating profit. A pharmacy could report a “net loss” if the pharmacy owner chose to pay himself or herself a larger bonus instead of reporting a positive net profit.

The NCPA Digest reports the sum of Owner Compensation and Net Operating Income as Owner's Discretionary Profit (ODP). Thus, ODP represents two of the three ways a pharmacy's gross profit dollars can be spent.

While NCPA no longer reports gross margins on prescription vs. non-prescription sales, I estimate that gross margins on prescription sales were 22.7% in 2013 vs. 22.5% in 2012. Here’s a look at prescription gross margins since the introduction of Medicare Part D.

[Click to Enlarge]

In 2013, average prescription revenues in the NCPA sample increased to $57.50, compared with $56.04 per prescription in 2012. Given the slight increase in gross margin, gross profit dollars per prescription grew by 3.5%, from $12.60 per prescription in 2012 to $13.03 per prescription in 2013.

The Digest's average per-pharmacy revenue increased slightly (+1.0%). However, average revenue has dropped slightly from its peak of $4.0 million, in 2009, to $3.9 million in 2013. The revenue decline is due to brand-to-generic substitution, not volume. Total prescriptions per pharmacy have increased over the past few years.

OBSERVATION 3: The average pharmacist owning a single pharmacy earned about $247,000 in 2013.

Since NCPA no longer publishes financial details, I multiplied last year’s median Owner’s Discretionary Profit (ODP) figure by average revenues. On a per-pharmacy basis, this figure grew, from $245K in 2012 to $247K in 2013 (+1%). The increase reflects higher pharmacy margins in the 2013 sample.

OBSERVATION 4: The average pharmacist owning multiple pharmacies earned about $900,000 in 2013.

The NCPA Digest reports that in 2013, 27% of the Digest’s sample owned two or more pharmacies. With a bit of algebra, I computed that this 27% of the sample owned an average of 3.6 pharmacies. The remaining 73% owned a single pharmacy. In either case, these owners must be pharmacists to meet the NCPA’s definition of “independent pharmacy.”

Put another way, the 2014 NCPA Digest implies that the owner of multiple pharmacies saw a slight decrease in average total earnings, from 2012’s $1,016,000 (=$245*4.2 pharmacies) to 2013’s $897,200 (=$247*3.6 pharmacies)—a decrease of $118.5K (-11.7%). The decrease is due entirely to the lower average number of pharmacies (3.6 vs. 4.2) in this year’s sample.

Total profits for multiple-pharmacy owner could be lower than this figure, because the owner may need to pay pharmacists to work in the different stores.

OBSERVATION 5: The total number of independent pharmacies continues to hold steady.

According to the NCPA’s counting, the total number of independent community pharmacies has remained roughly stable: 23,064 in 2010; 23,106 in 2011; 23,029 in 2012; and 22,814 in 2013. The appeal of ownership clearly hasn't dimmed. Note that NCPA’s figures are higher than those from other third-party sources.

Since NCPA has hidden the financial data, we don’t know how many pharmacies supposedly “operate at a loss.” Last year, the Digest claimed that 24.3% of pharmacies were operating at a loss, compared with 23.6% in 2011.

Miraculously, the industry has not been collapsing. And if you understand the above components of gross profit, you'll see why such "operating at a loss" figures are completely bogus. A net loss may simply mean that the owner drew a salary and bonus that pushed the business’s net profit figure into an accounting loss. As the data demonstrate, the profit story for pharmacy owners remains good.

The NCPA digest data provide the only publicly available look at the financial position of independent pharmacies.

In NCPA press releases, the digest data are used to compute that independent community pharmacies are an $88.8 billion “health care marketplace.” (NCPA multiplies the $3.9 million average revenue figure by 22,814 pharmacies.)

The digest’s profit data have been cited in sworn testimony to the U.S. Congress.

The data have been analyzed in peer-reviewed academic articles and were featured in an expert report written on behalf of NACDS and NCPA in their previous lawsuit over Average Manufacturer Price (AMP). I presume the data will be dragged out when NACDS and NCPA file their next lawsuit against the elusive AMP-based FULs.

Weaknesses

NCPA provide no transparency into the survey methodology. We aren't told the sample size or how the responses are collected. We also don't know who analyzed these data: NCPA or an independent third-party organization.

The NCPA data come from a self-selected sample. Pharmacies doing better or worse than average may not have returned the survey in equal proportions.

Year-over-year differences may not be statistically significant. NCPA does not provide confidence intervals around the Digest's point estimates.

The data were self-reported, not based on audited financial statements. Respondents could have altered their profit data to make it look better or worse than reality.

Many items on the survey instrument were not defined and therefore may have been interpreted differently by respondents.

I don't think you should describe what's happening to independent pharmacy as "steady". Stagnant, stalled, stuck, suckey... much better terms.

Like the mainstream media you take one statistic and draw a (horribly) wrong conclusion. How about some other statistics (facts, not opinions) that might be relevant to the state of independent pharmacy:

Change in U.S. population since 2000: up 12%Change in U.S. population over age 65: up 18%Change in number of Walgreens stores since 2000: up 173% (3000 to 8200)Number of independent pharmacies that closed in 2013 in Iowa alone: 40Number of Iowa counties that had at least one pharmacy 2 years ago: 99 (all)Number of Iowa counties that have at least one pharmacy now: 97Average size of Iowa counties: 500 sq. miles (Independents are closing in rural areas all over the country, Oregon in particular is having quite a problem, I just don't have those facts at hand...maybe you do.)

Most of your other conclusions assume that the Digest is a random sample of pharmacies (it's not) and that there is a statistically valid number of samples (which we don't know), so your "Observations" are pretty much random numbers cloaked in mathematics.

"Facts are stubborn things; and whatever may be our wishes, our inclinations, or the dictates of our passion, they cannot alter the state of facts and evidence." - John Adams, Second President of the United States

I still don't understand your point. My statement ("According to the NCPA’s counting, the total number of independent community pharmacies has remained roughly stable.") is 100% accurate when referring to the national figures. Clearly, the number of independents declined in Iowa and increased elsewhere. YMMV.

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels Institute, or any of its employees.